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Type and dose of heparin in Covid-19: Reply
We thank the authors for their comments and feedback on the 
International Society on Thrombosis and Haemostasis interim guid-
ance. Hypercoagulability is indeed a significant issue in Covid-19, 
and the hemostatic system is shifted markedly toward the procoag-
ulant side in these patients. However, we cannot yet be certain that 
unfractionated heparin (UFH) is better than low molecular weight 
heparin (LMWH) in this scenario. Although UFH has been used for 
several years, it does have practical issues, mainly with respect to 
the need for frequent monitoring using activated partial throm-
boplastin time.1,2 In addition, as the authors pointed out correctly, 
markedly increased acute phase reactants including fibrinogen could 
contribute to heparin resistance making the use of UFH problematic 
(much more than LMWH).2 Among the reasons for heparin resis-
tance, antithrombin deficiency is not common in Covid-19 patients, 
at least in the published literature.3 Despite these issues, UFH may 
still be preferred if there is marked renal impairment or need for re-
versibility for an urgent intervention.4 One of the latter situations is 
if the patients progress despite anticoagulant therapy. The authors 
of the letter had recently published a case series on the use of tissue 
plasminogen activator in C,-19 patients which is certainly a consider-
ation in patients who progress despite anticoagulant therapy.5
At the time of writing the interim document, our aim was to 
highlight the urgent need to consider thromboprophylaxis in all 
patients who require hospital admission for Covid-19 to mitigate 
poor outcomes from the marked hypercoagulability. We do recog-
nize that, since then, it has frequently been suggested that higher 
doses of LMWH be given to Covid-19 patients to prevent venous 
thromboembolism. However, there is no demonstration that stan-
dard prophylactic doses are insufficient to prevent it. Pulmonary 
vessel occlusions that are observed in severe Covid-19 patients 
are caused by pulmonary thrombi, whose pathogenesis is unclear 
but likely to be associated with the severe pulmonary inflamma-
tion. Concerning the type of heparin, we cannot be certain that 
one type is better than the other; in other words, it is difficult to 
say UFH is better than LMWH. LMWH was chosen in the guid-
ance because of the ease of use, no need for laboratory monitor-
ing, and familiarity among the spectrum of doctors with varying 
experience. The question of whether therapeutic doses of either 
UFH or LMWH should be considered for all patients is currently 
unknown and the authors would currently reserve such a dose for 
those who have confirmed thrombosis including filter thrombosis. 
We are aware however that therapeutic dose is being administered 
in some centers where there is very high suspicion of pulmonary 
embolism and imaging is impractical. Although these approaches 
are reasonable, we stress that these approaches are undertaken 
in a trial setting.
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